Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Share-based Compensation: 2015-2024

Historic Share-based Compensation for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to $13.1 million.

  • UroGen Pharma's Share-based Compensation fell 13.24% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 2.30%. This contributed to the annual value of $13.1 million for FY2024, which is 40.28% up from last year.
  • As of FY2024, UroGen Pharma's Share-based Compensation stood at $13.1 million, which was up 40.28% from $9.3 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Share-based Compensation ranged from a high of $28.0 million in FY2020 and a low of $9.3 million during FY2023.
  • For the 3-year period, UroGen Pharma's Share-based Compensation averaged around $11.0 million, with its median value being $10.6 million (2022).
  • In the last 5 years, UroGen Pharma's Share-based Compensation slumped by 54.22% in 2022 and then skyrocketed by 40.28% in 2024.
  • Over the past 5 years, UroGen Pharma's Share-based Compensation (Yearly) stood at $28.0 million in 2020, then decreased by 17.53% to $23.1 million in 2021, then crashed by 54.22% to $10.6 million in 2022, then declined by 11.68% to $9.3 million in 2023, then soared by 40.28% to $13.1 million in 2024.